Radioactive 'Tumor Seeker' drug tested in patients with advanced cancers
NCT ID NCT06639191
Summary
This is a very early study to test the safety of a new radioactive drug called [177Lu]Lu-AKIR001 in adults with advanced solid tumors that have a specific marker called CD44v6. The main goal is to find out what side effects occur and how much of the drug the body can handle. Researchers will also track where the drug goes in the body and see if it has any effect on shrinking tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND ANAPLASTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karolinska University hospital
RECRUITINGStockholm, Stockholm County, 17176, Sweden
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.